RxDoctor Payments DataLook up a doctor →

Aung Bajaj, MD

Hematology & Oncology · Tucson, AZNPI 1598177255

Payments from drug & device makers

$521,545in general payments, 2019–2025

Across 555 payments — averaging $939.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$447K
  • Acerta Pharma LLC$27K
  • E.r. Squibb & Sons, L.L.C.$20K
  • AVEO Pharmaceuticals, Inc.$11K
  • AstraZeneca$2K
  • Johnson & Johnson$2K
  • plus $13K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exelixis Inc.47$446,677
Acerta Pharma LLC2$27,110
E.r. Squibb & Sons, L.L.C.13$20,046
AVEO Pharmaceuticals, Inc.4$10,919
AstraZeneca(2 entities)26$2,068
Johnson & Johnson(2 entities)29$1,890
Janssen Scientific Affairs, LLC1$1,515
Taiho Oncology, Inc.6$1,498
Bristol Myers Squibb53$809
Novartis42$770
Beigene USA, Inc.6$732
Pfizer36$601
Incyte Corporation12$475
Bayer22$432
Astellas Pharma US Inc14$422
Amgen17$379
Gilead(2 entities)17$350
Sanofi13$344
Sumitomo Pharma America, Inc.15$341
Mirati Therapeutics, Inc.10$283
Genentech USA, Inc.12$269
AbbVie13$268
GSK11$202
Daiichi Sankyo Inc.6$201
Merck7$196
Genmab U.S., Inc.7$194
Takeda Pharmaceuticals U.S.A., Inc.9$188
Eisai Inc.9$185
Array Biopharma Inc10$170
Seagen Inc.8$158
Apellis Pharmaceuticals, Inc.3$141
Dova Pharmaceuticals2$139
Lilly USA, LLC8$133
Regeneron Healthcare Solutions, Inc.6$133
Blueprint Medicines Corporation6$121
Sobi, Inc2$109
Pharmacosmos Therapeutics Inc.4$92
Springworks Therapeutics, Inc.4$85
Stemline Therapeutics Inc.4$83
Sanofi-aventis U.S. LLC1$70
Kyowa Kirin, Inc.4$69
Jazz Pharmaceuticals Inc.2$59
Rigel Pharmaceuticals, Inc.3$54
Myovant Sciences Inc.3$54
CTI Biopharma Corp.2$53
Ipsen Biopharmaceuticals, Inc3$48
Pharmacyclics LLC, An Abbvie Company2$48
Puma Biotechnology, Inc.2$45
Sun Pharmaceutical Industries Inc.2$36
Pharmaessentia USA Corporation2$36
Karyopharm Therapeutics Inc.1$33
Boehringer Ingelheim1$26
Alnylam Pharmaceuticals Inc.1$25
ADC Therapeutics America, Inc.1$24
Dendreon Pharmaceuticals LLC1$19
EMD Serono, Inc.1$18
Verity Pharmaceuticals Inc.1$18
Morphosys, US Inc.1$17
Aurobindo Pharma USA, Inc.1$17
Adaptive Biotechnologies Corporation1$14

How this compares

$521,545 in reported general payments places this provider in the 75th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$3,523,290
Medicare patients
626
Services billed
200,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →